FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366602181> ?p ?o ?g. }

• W4366602181 endingPage "10714" @default.
• W4366602181 startingPage "10704" @default.
• W4366602181 abstract "Abstract Aim Pyrotinib (an irreversible pan‐ErbB small‐molecular tyrosine kinase inhibitor) was approved in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer and showed great antitumor activity in preclinical studies of gastric cancer (GC). This study was first designed to prospectively assess pyrotinib in pretreated HER2‐positive GC. Methods This multicenter, phase I study followed a standard “3 + 3” design and included two parts. In the pyrotinib part, pyrotinib was administered orally, once per day at dose levels of 240, 320, 400, and 480 mg. In the pyrotinib plus docetaxel part, patients received pyrotinib (qd, d1‐21, q3W) combined with docetaxel (60 mg/m 2 , d1, q3W) at dose levels of 240, 320, and 400 mg. Primary endpoints were to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of pyrotinib as monotherapy or coadministered with docetaxel. Results A total of 25 patients were enrolled and received pyrotinib ( n = 15) or pyrotinib plus docetaxel ( n = 10). One DLT was observed in pyrotinib monotherapy part (Grade 3 uncontrolled diarrhea after supportive care) and pyrotinib plus docetaxel part (Grade 4 neutropenia and leukopenia). In the pyrotinib monotherapy part, MTD was not reached. Diarrhea, anemia, neutropenia, and leukopenia were the most common treatment‐related adverse events (TRAEs). The RP2D for pyrotinib monotherapy was recommended as 400 mg. After combining with docetaxel, the risk of leukopenia and neutropenia was increased. Grade ≥3 TRAEs were reported for four patients in the monotherapy part and for eight patients in the combination part. Mean t 1/2 was approximately 20 h. Pyrotinib exposure was dose‐dependent with a nonlinear relationship versus dose. There were five patients who had confirmed partial response (monotherapy: one each at 240, 400, and 480 mg dose cohort; combination therapy: two at 240 mg dose cohort), resulting in an objective response rate of 21% and 20%, respectively. Conclusions Pyrotinib alone and combined with docetaxel showed acceptable toxicities in patients with pretreated HER2‐positive GC. Trial Registration This study was registered with ClinicalTrials.gov , NCT02378389." @default.
• W4366602181 created "2023-04-23" @default.
• W4366602181 creator A5006012404 @default.
• W4366602181 creator A5006423482 @default.
• W4366602181 creator A5006511913 @default.
• W4366602181 creator A5011527639 @default.
• W4366602181 creator A5013718591 @default.
• W4366602181 creator A5034342116 @default.
• W4366602181 creator A5035535613 @default.
• W4366602181 creator A5042136777 @default.
• W4366602181 creator A5046118596 @default.
• W4366602181 creator A5052386864 @default.
• W4366602181 creator A5054785361 @default.
• W4366602181 creator A5058408659 @default.
• W4366602181 creator A5059392900 @default.
• W4366602181 creator A5068252474 @default.
• W4366602181 creator A5072537482 @default.
• W4366602181 creator A5073995543 @default.
• W4366602181 creator A5074564259 @default.
• W4366602181 date "2023-04-20" @default.
• W4366602181 modified "2023-10-18" @default.
• W4366602181 title "Pyrotinib alone or in combination with docetaxel in refractory <scp>HER2</scp>‐positive gastric cancer: A dose‐escalation phase I study" @default.
• W4366602181 cites W2008322008 @default.
• W4366602181 cites W2016283072 @default.
• W4366602181 cites W2017176432 @default.
• W4366602181 cites W2100439220 @default.
• W4366602181 cites W2185378752 @default.
• W4366602181 cites W2338611117 @default.
• W4366602181 cites W2610910101 @default.
• W4366602181 cites W2613098450 @default.
• W4366602181 cites W2897683782 @default.
• W4366602181 cites W2898867204 @default.
• W4366602181 cites W2899138638 @default.
• W4366602181 cites W2932398125 @default.
• W4366602181 cites W2976352116 @default.
• W4366602181 cites W3046213609 @default.
• W4366602181 cites W3048937511 @default.
• W4366602181 cites W3113542367 @default.
• W4366602181 cites W3159546116 @default.
• W4366602181 cites W3159805754 @default.
• W4366602181 cites W3206805169 @default.
• W4366602181 cites W4210675366 @default.
• W4366602181 cites W4246328459 @default.
• W4366602181 cites W4366602181 @default.
• W4366602181 doi "https://doi.org/10.1002/cam4.5830" @default.
• W4366602181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37081722" @default.
• W4366602181 hasPublicationYear "2023" @default.
• W4366602181 type Work @default.
• W4366602181 citedByCount "1" @default.
• W4366602181 countsByYear W43666021812023 @default.
• W4366602181 crossrefType "journal-article" @default.
• W4366602181 hasAuthorship W4366602181A5006012404 @default.
• W4366602181 hasAuthorship W4366602181A5006423482 @default.
• W4366602181 hasAuthorship W4366602181A5006511913 @default.
• W4366602181 hasAuthorship W4366602181A5011527639 @default.
• W4366602181 hasAuthorship W4366602181A5013718591 @default.
• W4366602181 hasAuthorship W4366602181A5034342116 @default.
• W4366602181 hasAuthorship W4366602181A5035535613 @default.
• W4366602181 hasAuthorship W4366602181A5042136777 @default.
• W4366602181 hasAuthorship W4366602181A5046118596 @default.
• W4366602181 hasAuthorship W4366602181A5052386864 @default.
• W4366602181 hasAuthorship W4366602181A5054785361 @default.
• W4366602181 hasAuthorship W4366602181A5058408659 @default.
• W4366602181 hasAuthorship W4366602181A5059392900 @default.
• W4366602181 hasAuthorship W4366602181A5068252474 @default.
• W4366602181 hasAuthorship W4366602181A5072537482 @default.
• W4366602181 hasAuthorship W4366602181A5073995543 @default.
• W4366602181 hasAuthorship W4366602181A5074564259 @default.
• W4366602181 hasBestOaLocation W43666021811 @default.
• W4366602181 hasConcept C121608353 @default.
• W4366602181 hasConcept C126322002 @default.
• W4366602181 hasConcept C143998085 @default.
• W4366602181 hasConcept C197934379 @default.
• W4366602181 hasConcept C2776694085 @default.
• W4366602181 hasConcept C2777063308 @default.
• W4366602181 hasConcept C2778850193 @default.
• W4366602181 hasConcept C2780873365 @default.
• W4366602181 hasConcept C2781190966 @default.
• W4366602181 hasConcept C71924100 @default.
• W4366602181 hasConcept C90924648 @default.
• W4366602181 hasConcept C98274493 @default.
• W4366602181 hasConceptScore W4366602181C121608353 @default.
• W4366602181 hasConceptScore W4366602181C126322002 @default.
• W4366602181 hasConceptScore W4366602181C143998085 @default.
• W4366602181 hasConceptScore W4366602181C197934379 @default.
• W4366602181 hasConceptScore W4366602181C2776694085 @default.
• W4366602181 hasConceptScore W4366602181C2777063308 @default.
• W4366602181 hasConceptScore W4366602181C2778850193 @default.
• W4366602181 hasConceptScore W4366602181C2780873365 @default.
• W4366602181 hasConceptScore W4366602181C2781190966 @default.
• W4366602181 hasConceptScore W4366602181C71924100 @default.
• W4366602181 hasConceptScore W4366602181C90924648 @default.
• W4366602181 hasConceptScore W4366602181C98274493 @default.
• W4366602181 hasFunder F4320321001 @default.
• W4366602181 hasIssue "9" @default.
• W4366602181 hasLocation W43666021811 @default.
• W4366602181 hasLocation W43666021812 @default.
• W4366602181 hasLocation W43666021813 @default.

• next